Literature DB >> 24331845

Comparison of whole-body PET/CT and PET/MRI in breast cancer patients: lesion detection and quantitation of 18F-deoxyglucose uptake in lesions and in normal organ tissues.

Leonardo Pace1, Emanuele Nicolai2, Angelo Luongo3, Marco Aiello4, Onofrio A Catalano5, Andrea Soricelli6, Marco Salvatore7.   

Abstract

PURPOSE: To compare the performance of PET/MRI imaging using MR attenuation correction (MRAC) (DIXON-based 4-segment -map) in breast cancer patients with that of PET/CT using CT-based attenuation correction and to compare the quantification accuracy in lesions and in normal organ tissues.
METHODS: A total of 36 patients underwent a whole-body PET/CT scan 1h after injection and an average of 62 min later a second scan using a hybrid PET/MRI system. PET/MRI and PET/CT were compared visually by rating anatomic allocation and image contrast. Regional tracer uptake in lesions was quantified using volumes of interest, and maximal and mean standardized uptake values (SUVmax and SUVmean, respectively) were calculated. Metabolic tumor volume (MTV) of each lesion was computed on PET/MRI and PET/CT. Tracer uptake in normal organ tissue was assessed as SUVmax and SUVmean in liver, spleen, left ventricular myocardium, lung, and muscle.
RESULTS: Overall 74 FDG positive lesions were visualized by both PET/CT and PET/MRI. No significant differences in anatomic allocation scores were found between PET/CT and PERT/MRI, while contrast score of lesions on PET/MRI was significantly higher. Both SUVmax and SUVmean of lesions were significantly higher on PET/MRI than on PET/CT, with strong correlations between PET/MRI and PET/CT data (ρ=0.71-0.88). MTVs of all lesions were 4% lower on PET/MRI than on PET/CT, but no statistically significant difference was observed, and an excellent correlation between measurements of MTV with PET/MRI and PET/CT was found (ρ=0.95-0.97; p<0.0001). Both SUVmax and SUVmean were significantly lower by PET/MRI than by PET/CT for lung, liver and muscle, no significant difference was observed for spleen, while either SUVmax and SUVmean of myocardium were significantly higher by PET/MRI. High correlations were found between PET/MRI and PET/CT for both SUVmax and SUVmean of the left ventricular myocardium (ρ=0.91; p<0.0001), while moderate correlations were found for the other normal organ tissues (ρ=0.36-0.61; p<0.05).
CONCLUSIONS: PET/MRI showed equivalent performance in terms of qualitative lesion detection to PET/CT. Despite significant differences in tracer uptake quantification, due to either methodological and biological factors, PET/MRI and PET/CT measurements in lesions and normal organ tissues correlated well. This study demonstrates that integrated whole-body PET/MRI is feasible in a clinical setting with high quality and in a short examination time.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Breast cancer; Hybrid imaging; MTV; Oncology; PET/CT; PET/MRI; SUV

Mesh:

Substances:

Year:  2013        PMID: 24331845     DOI: 10.1016/j.ejrad.2013.11.002

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  47 in total

Review 1.  Present and future role of FDG-PET/CT imaging in the management of breast cancer.

Authors:  Kazuhiro Kitajima; Yasuo Miyoshi
Journal:  Jpn J Radiol       Date:  2016-01-05       Impact factor: 2.374

2.  Quantitative carotid PET/MR imaging: clinical evaluation of MR-Attenuation correction versus CT-Attenuation correction in (18)F-FDG PET/MR emission data and comparison to PET/CT.

Authors:  Jason Bini; Philip M Robson; Claudia Calcagno; Mootaz Eldib; Zahi A Fayad
Journal:  Am J Nucl Med Mol Imaging       Date:  2015-02-15

3.  (18) F-FDG PET/CT for initial staging in breast cancer patients - Is there a relevant impact on treatment planning compared to conventional staging modalities?

Authors:  J Krammer; A Schnitzer; C G Kaiser; K A Buesing; E Sperk; J Brade; S Wasgindt; M Suetterlin; S O Schoenberg; E J Sutton; K Wasser
Journal:  Eur Radiol       Date:  2015-02-15       Impact factor: 5.315

4.  Time to move to PET-MR for cardiovascular imaging.

Authors:  Olivier Lairez; Philip M Robson; Zahi A Fayad
Journal:  J Nucl Cardiol       Date:  2015-07-02       Impact factor: 5.952

5.  Clinical utility of 18F-FDG-PET/MR for preoperative breast cancer staging.

Authors:  Diomidis Botsikas; Anastasia Kalovidouri; Minerva Becker; Michele Copercini; Dahila Amal Djema; Alexandre Bodmer; Sindy Monnier; Christoph D Becker; Xavier Montet; Benedicte M A Delattre; Osman Ratib; Valentina Garibotto; Claire Tabouret-Viaud
Journal:  Eur Radiol       Date:  2015-10-17       Impact factor: 5.315

6.  Integrated versus separate reading of F-18 FDG-PET/CT and MRI for abdominal malignancies - effect on staging outcomes and diagnostic confidence.

Authors:  Lisa A Min; Wouter V Vogel; Max J Lahaye; Monique Maas; Maarten L Donswijk; Erik Vegt; Miranda Kusters; Henry J Zijlmans; Katarzyna Jóźwiak; Sander Roberti; Regina G H Beets-Tan; Doenja M J Lambregts
Journal:  Eur Radiol       Date:  2019-05-22       Impact factor: 5.315

7.  What is the diagnostic performance of 18-FDG-PET/MR compared to PET/CT for the N- and M- staging of breast cancer?

Authors:  Diomidis Botsikas; Ilias Bagetakos; Marlise Picarra; Ana Carolina Da Cunha Afonso Barisits; Sana Boudabbous; Xavier Montet; Giang Thanh Lam; Ismini Mainta; Anastasia Kalovidouri; Minerva Becker
Journal:  Eur Radiol       Date:  2018-09-28       Impact factor: 5.315

Review 8.  Current Status of Hybrid PET/MRI in Oncologic Imaging.

Authors:  Andrew B Rosenkrantz; Kent Friedman; Hersh Chandarana; Amy Melsaether; Linda Moy; Yu-Shin Ding; Komal Jhaveri; Luis Beltran; Rajan Jain
Journal:  AJR Am J Roentgenol       Date:  2015-10-22       Impact factor: 3.959

9.  Prediction of standard-dose brain PET image by using MRI and low-dose brain [18F]FDG PET images.

Authors:  Jiayin Kang; Yaozong Gao; Feng Shi; David S Lalush; Weili Lin; Dinggang Shen
Journal:  Med Phys       Date:  2015-09       Impact factor: 4.071

Review 10.  18F-FDG PET/CT and PET/MRI Perform Equally Well in Cancer: Evidence from Studies on More Than 2,300 Patients.

Authors:  Claudio Spick; Ken Herrmann; Johannes Czernin
Journal:  J Nucl Med       Date:  2016-01-07       Impact factor: 10.057

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.